Vitamin B3 Shows Promise for COPD Treatment, Offering Hope for Millions

A recent study from the University of Copenhagen indicates that nicotinamide riboside, a form of vitamin B3, may significantly reduce lung inflammation in patients with Chronic Obstructive Pulmonary Disease (COPD), SciTech Daily reported yesterday.

This double-blind, placebo-controlled trial involved 40 COPD patients and 20 healthy controls. Those receiving vitamin B3 showed a 53% decrease in the inflammation marker interleukin 8 (IL-8) after six weeks, with a further reduction of 63% after 12 weeks.

COPD, affecting around 600 million people globally, leads to severe breathing difficulties and increased risks of respiratory infections. The study also found that COPD patients had lower levels of NAD, a molecule linked to aging, which was increased with vitamin B3 treatment.

While the results are promising, researchers stress the need for larger studies to confirm these findings and explore the long-term effects of vitamin B3 as a potential COPD treatment. This research could pave the way for new therapeutic options for millions suffering from this debilitating disease.